Effects of Patient-Controlled Transcutaneous Electrical Acupoint Stimulation on Cancer Induced Bone Pain Relief in Patients with Non-Small Cell Lung Cancer: Study Protocol for a Randomized Controlled Trial
DOI: https://doi.org/10.2147/jpr.s437296
IF: 2.8319
2024-03-27
Journal of Pain Research
Abstract:Zhengyi Lyu, 1, &ast Qiongying Shen, 1, &ast Shuxin Tian, 1, &ast Liyan Gong, 2 Haizhou Lou, 3 Guanai Bao, 2 Zhuoxuan Wu, 3 Chao Lu, 2 Weiping Zhang, 4 Rui Huang, 5 Conghua Ji, 6 Siyi Zheng, 1 Wei Pan, 1 Yinyin Ying, 4 Jianwei Jin, 4 Yi Liang 4 1 The Third Clinical Medical College of Zhejiang Chinese Medical University, Hangzhou, Zhejiang, People's Republic of China; 2 Zhejiang Cancer Hospital, Hangzhou, Zhejiang, People's Republic of China; 3 Department of Medical Oncology, Sir Run Run Shaw Hospital, Hangzhou, Zhejiang, People's Republic of China; 4 Department of Acupuncture, the Third Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, Zhejiang, People's Republic of China; 5 Department of Acupuncture and Tuina, Wenzhou Central Hospital, Wenzhou, Zhejiang, People's Republic of China; 6 Zhejiang Chinese Medical University, Hangzhou, Zhejiang, People's Republic of China &astThese authors contributed equally to this work Correspondence: Yi Liang, Department of Acupuncture, the Third Affiliated Hospital of Zhejiang Chinese Medical University, 219 Moganshan Road, Hangzhou City, Zhejiang Province, 310053, People's Republic of China, Email Background: Transcutaneous Electrical Acupoint Stimulation (TEAS) therapy opens up the possibility for individuals with Cancer-induced bone pain (CIBP) to receive a home-based, patient-controlled approach to pain management. The aim of this study is designed to evaluate the efficacy of patient-controlled TEAS (PC-TEAS) for relieving CIBP in patients with non-small cell lung cancer (NSCLC). Methods/Design: This is a study protocol for a prospective, triple-blind, randomized controlled trial. We anticipate enrolling 188 participants with NSCLC bone metastases who are also using potent opioid analgesics from 4 Chinese medical centers. These participants will be randomly assigned in a 1:1 ratio to either the true PC-TEAS or the sham PC-TEAS group. All participants will receive standard adjuvant oncology therapy. The true group will undergo patient-controlled TEAS intervention as needed, while the sham group will follow the same treatment schedule but with non-conductive gel patches. Each treatment course will span 7 days, with a total of 4 courses administered. There will be 4 assessment time points: baseline, the conclusion of weeks 4, 8, and 12. The primary outcome of this investigation is the response rate of the average pain on the Brief Pain Inventory (BPI) scale at week 4 after treatment. Secondary outcomes include pain related indicators, quality of life scale, mood scales, and routine blood counts on the assessment days. Any adverse events will be promptly addressed and reported if they occur. We will manage trial data using the EDC platform, with a data monitoring committee providing regular quality oversight. Discussion: PC-TEAS interventions offer an attempt to achieve home-based acupuncture treatment and the feasibility of achieving triple blinding in acupuncture research. This study is designed to provide more rigorous trial evidence for the adjuvant treatment of cancer-related pain by acupuncture and to explore a safe and effective integrative medicine scheme for CIBP. Trial Registration: ClinicalTrials.gov NCT05730972, registered February 16, 2023. Keywords: bone cancer pain, TEAS, transcutaneous electrical nerve stimulation, patient-controlled analgesia, integrative medicine, home-based treatment Cancer-induced bone pain (CIBP) constitutes a significant issue in non-small cell lung cancer (NSCLC). The prevalence of bone metastasis in NSCLC varies from 20% to over 60%, 1–4 with 80% of these patients encountering CIBP. 4,5 Pain stands as one of the most prevalent skeletal-related events of bone metastasis, exerting a detrimental impact on both quality of life (QoL) and performance status. 3 While radiation therapy serves as the foremost recommended standard for alleviating painful bone metastases, its application remains limited to patients with a constrained count of metastases. The conventional therapeutic approach to managing CIBP primarily relies on pharmaceutical intervention. Drawing from adjuvant anticancer therapy and bone-protective treatment, pharmacological analgesic regimens adhere to the World Health Organization (WHO) three-level analgesia ladder, encompassing non-opioid and opioid treatments. 6 Nonetheless, up to 45% of early-stage cancer patients and 75% of advanced cancer patients encounter inadequate pain control at least once. 7</su -Abstract Truncated-
clinical neurology